Our IQVIA MAPA team discuss the changes the NHS will face this year, including transformational changes, changes within the private market and the opportunities this brings for the life sciences industry to enable access to treatments quicker. Watch the full discussion here: https://bit.ly/3WfWfKF
IQVIA UK and Ireland ’s Post
More Relevant Posts
-
Need to start thinking about your Strat Plan? Take a listen to this take on changes in the NHS and the potential impact on UK pharma marketing.
Our IQVIA MAPA team discuss the changes the NHS will face this year, including transformational changes, changes within the private market and the opportunities this brings for the life sciences industry to enable access to treatments quicker. Watch the full discussion here: https://bit.ly/3WfWfKF
-
In April 2022, the FDA issued a draft guidance to improve clinical trial enrollment of participants from underrepresented racial and ethnic populations. Commonly referred to as the Diversity Plan, this guidance is a framework for establishing clinical trial patient populations reflective of the therapeutic’s target patient population. Learn more about the latest regulations in this white paper.
-
Executive Alliance Director, Biopharma Partnerships, Clinical Research Business of Thermo Fisher Scientific
In April 2022, the FDA issued a draft guidance to improve clinical trial enrollment of participants from underrepresented racial and ethnic populations. Commonly referred to as the Diversity Plan, this guidance is a framework for establishing clinical trial patient populations reflective of the therapeutic’s target patient population. Learn more about the latest regulations in this white paper.
Reduce Health Care Disparities White Paper | PPD Inc
https://www.ppd.com
-
In April 2022, the FDA issued a draft guidance to improve clinical trial enrollment of participants from underrepresented racial and ethnic populations. Commonly referred to as the Diversity Plan, this guidance is a framework for establishing clinical trial patient populations reflective of the therapeutic’s target patient population. Learn more about the latest regulations in this white paper.
Reduce Health Care Disparities White Paper | PPD Inc
https://www.ppd.com
-
MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Haig et al. developed a comprehensive framework for assessing the value of novel patient-facing Digital Health Technologies (DHTs) used in chronic disease management. The authors utilized a combination of literature review and primary data collection via a three-round web-Delphi exercise involving stakeholders from the USA, the UK, and Germany, resulting in a framework comprising 33 stable indicators across various domains. This framework elicits stakeholder value preferences to guide efficient and evidence-based decision-making in assessing these technologies: Learn more here: https://lnkd.in/e_mQMJnD
-
-
The healthcare industry is shifting towards patient-centered care and centralized data management. Tiga Healthcare Technologies user-friendly Personal Health Record (PHR) System and our ongoing partnerships, which focus on patient engagement, solidify our leadership in the evolving healthcare IT framework. Thanks to PHR, patients securely access their health records 24/7, boosting patient-centered care and more informed decision-making processes. Patients, healthcare professionals and authorities benefit from real-time information and powerful data management. Our PHR delivers more than these advantages and aligns with recent research, such as European Parliament's recent policy options on multi-country collaboration for rare diseases. Among the six policy options for rare diseases, utilizing electronic health records and secure access to real-time medical data for patients is essential. In essence, PHR opens the road for us to lead patient-centered healthcare IT. It streamlines healthcare delivery for impactful solutions globally. Let's shape the future together, as always! More on the European Parliament report on rare diseases: https://lnkd.in/dCZ4qJAV #Tiga #HealthcareIT #PharmaIT #PHR #PatientEngagement
Addressing challenges to European multi-country collaboration models for rare diseases | Think Tank | European Parliament
europarl.europa.eu
-
MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Haig et al. developed a comprehensive framework for assessing the value of novel patient-facing Digital Health Technologies (DHTs) used in chronic disease management. The authors utilized a combination of literature review and primary data collection via a three-round web-Delphi exercise involving stakeholders from the USA, the UK, and Germany, resulting in a framework comprising 33 stable indicators across various domains. This framework elicits stakeholder value preferences to guide efficient and evidence-based decision-making in assessing these technologies: Learn more here: https://lnkd.in/ecKZqsde
-
-
Clinical & Scientific Lead International | Senior Medical Director | Machine Learning | Oncology Real World Data
Delighted to see this study on Transportability co-authored by Flatiron Health and NICE - National Institute for Health and Care Excellence published in the BMJ Open. For more on the findings and why this matters, visit: http://spkl.io/6041fwOfl
There's a growing trend of using real-world data from different countries to support clinical trial data, especially in HTA decisions. However, this raises questions about whether data from one country can apply to another — a concept called transportability. After accounting for differences in population characteristics, this research led by Flatiron Health and NICE - National Institute for Health and Care Excellence found overall survival for patients receiving first line treatment for aNSCLC were similar in the US and UK, suggesting that when local data is unavailable, US data can serve as a reliable alternative, as adjusted US values closely correspond with observed outcomes for UK patients. This research validates transportability as a methodology for using data across borders, with the potential to improve standards of care, speed to access treatments, and provide more confidence in how medicines perform. For more on the findings and why this matters, visit: http://spkl.io/6041fwOfl
-
Who tests external validity? Páll Jónsson and I had the idea for this study in 2019. Now our paper with Seamus Kent, Stephen J. Duffield, Philani Mpofu, Jane Adam, Brennan Beal, Trevor Royce MD MPH FASCO, Jyotsna Kasturi, Arun Sujenthiran MD, Páll Jónsson is published in BMJ Open. Do differences in the healthcare systems of England and America modify the outcomes for people with cancer? Read it here: https://lnkd.in/e_qneGRn
There's a growing trend of using real-world data from different countries to support clinical trial data, especially in HTA decisions. However, this raises questions about whether data from one country can apply to another — a concept called transportability. After accounting for differences in population characteristics, this research led by Flatiron Health and NICE - National Institute for Health and Care Excellence found overall survival for patients receiving first line treatment for aNSCLC were similar in the US and UK, suggesting that when local data is unavailable, US data can serve as a reliable alternative, as adjusted US values closely correspond with observed outcomes for UK patients. This research validates transportability as a methodology for using data across borders, with the potential to improve standards of care, speed to access treatments, and provide more confidence in how medicines perform. For more on the findings and why this matters, visit: http://spkl.io/6041fwOfl
-
Only ONE WEEK left to share your insights into clinical trials and treatment needs through the latest #ALSFocus survey. Your responses will help convey the urgent needs of the #ALS community and improve future trials. Take the survey TODAY: alsfocus.org!
-
